Bone Loss After Denosumab: Only Partial Protection with Zoledronate
A case series of six women with postmenopausal osteoporosis who had received continuous denosumab for 7 years and were then given a single infusion of zoledronate (5 mg) is reported. During denosumab treatment, bone mineral density (BMD) … Leer más